Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial
de Wit, J.
van Mierlo, M.M.F.
van Veldhuizen, J.
van Doorn, M.B.A.
Letter to the editor. Staphylococcus aureus density is increased in many patients with atopic dermatitis (AD) and is thought to contribute to disease pathogenesis, interacting with an altered skin barrier and immunologic changes.1 S aureus might induce or aggravate inflammation through different mechanisms, for example through excretion of virulence factors, even if the S aureus overgrowth is primarily caused by other factors.2 Current guidelines only recommend antimicrobial therapy directed against S aureus in patients with clinically infected AD based on a Cochrane review in which no clinical benefit of short-term antimicrobial treatment in patients with noninfected AD was found.
To reference this document use:
Journal of Allergy and Clinical Immunology, 144 (3), 860-863